Halozyme Therapeutics — Ethics Grade C

Halozyme Therapeutics receives an overall ethics grade of C (45/100) on CancelCo's corporate accountability database. Sector: Healthcare. Market cap: Mid Cap.

Category scores

• labor: 60
• privacy: 70
• consumer: 40
• environment: 75
• humanRights: 55

Documented incidents (3)

• Enabling Patent Evergreen (medium, 2022) — The company's technology is used by larger biotechs to convert IV drugs into subcutaneous injections. Critics argue this is used solely to extend patent protection and block cheaper generics.
• Auto-Injector Mechanical Failure (medium, 2021) — Before acquisition, Antares faced recalls for auto-injectors that failed to deliver the correct dose of testosterone. The failure was linked to manufacturing defects at a primary facility.
• Lack of Clinical Data Access (low, 2023) — Advocacy groups identified Halozyme as having lower transparency regarding clinical trial participant diversity and the sharing of de-identified patient data for secondary research.

Documented good deeds

• Reducing Treatment Duration — The company’s Enhanze technology reduces drug administration time from hours to minutes, significantly improving quality of life for cancer patients.

Ethical alternatives

• Regeneron — Stronger focus on original discovery and higher internal R&D transparency.